Hemorrhagic Shock Clinical Trial
Official title:
The Use of rFVIIa in Trauma Patients: A WTA/AAST Multi-Center Case Registry
Trauma surgeons throughout the US have begun using recombinant activated factor VII (rFVIIa)
to control severe hemorrhage following injury when traditional measures have failed. Despite
promising results from several small studies, there remain several unanswered questions
regarding the use of this relatively expensive product in injured patients including:
- The timing of administration
- Selection of appropriate patients who are most likely to benefit
- The effective dose in injured patients
- The potential need for repeated dosing
- The need for administration of platelets and correction of acidosis prior to
administering the first dose
- The risks associated with the use of rFVIIa including venous and/or arterial thrombosis
- The potential for rFVIIa to cause or aggravate post-injury organ failure and/or
infectious complications
- An analysis of cost versus benefit The purpose of this study is to collect a large
sample of patients from multiple institutions in order to address the issues listed
above. To this end, the Western Trauma Association Foundation is sponsoring a
multi-center case registry for patients receiving rFVIIa for treatment of uncontrolled
hemorrhage.
This is a prospective, multi-center case registry that seeks to combine the collective experience with the use of rFVIIa at UCSF/SFGH with other trauma centers. The study is being conducted under the auspices of the Western Trauma Association and the American Association of the Surgery of Trauma. Both organizations have a long history of successfully completing multi-center studies. The outcomes to be used in this study are: 1) survival, 2) amount of blood products infused before and after rFVIIa, 3) coagulation factors (PTT, INR) before and after, and 4) the surgeon's assessment of hemostasis. Data will also be analyzed to determine the cost effectiveness of rFVIIa when compared with other methods of treating severe hemorrhage, primarily administration of blood products. Finally, the incidence of complications and thrombotic events after drug administration will be evaluated. ;
Observational Model: Cohort, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04149171 -
Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage
|
Phase 3 | |
Not yet recruiting |
NCT06070350 -
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
|
Phase 3 | |
Not yet recruiting |
NCT02880163 -
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
|
N/A | |
Completed |
NCT02924792 -
Sternal Intraosseous Transfusion of Autologous Whole Blood: A Comparison of Flow Rates and Degree of Hemolysis
|
N/A | |
Terminated |
NCT00750997 -
Hypertonic Modulation of Inflammation Following Injury
|
N/A | |
Terminated |
NCT03477006 -
Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial
|
Phase 3 | |
Not yet recruiting |
NCT04987411 -
Detection of Exhaled Methane Levels in Hemorrhagic Shock
|
||
Recruiting |
NCT04610814 -
Blood Transfusion by Boston MedFlight Registry
|
||
Completed |
NCT02071290 -
Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock
|
N/A | |
Completed |
NCT03535441 -
HMGB1 Release From Hemorrhagic Shock Patients
|
||
Completed |
NCT03480555 -
Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients
|
N/A | |
Completed |
NCT03402035 -
Shock, Whole Blood, and Assessment of TBI S.W.A.T. (LITES TO 2)
|
||
Completed |
NCT05081063 -
Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
|
Phase 3 | |
Recruiting |
NCT03235921 -
Use of Nitroglycerine to Improve Signs of Poor Peripheral Perfusion in Patients With Traumatic Hemorrhagic Shock
|
Phase 2 | |
Active, not recruiting |
NCT03469947 -
California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA
|
Phase 3 | |
Completed |
NCT01411852 -
Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma
|
Phase 2 | |
Withdrawn |
NCT01221389 -
Study Using Plasma for Patients Requiring Emergency Surgery
|
Phase 4 | |
Recruiting |
NCT03406598 -
Bedside Visual Analysis of Sublingual Microcirculation in Shock Patients
|
||
Completed |
NCT00379522 -
Vasopressin in Traumatic Hemorrhagic Shock Study
|
Phase 2/Phase 3 | |
Completed |
NCT01433276 -
Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock
|
Phase 3 |